Immune globulin (human) is a Antibody and Blood Derivative owned by Hualan Biological Engineering, and is involved in 1 clinical trial, which is ongoing.

The lgG antibodies of broad-spectrum anti-virus, bacteria and other pathogens contained as well as the immune network formed by the immunoglobulin idiotypic antibody contribute the dual therapeutic effects as immune replacement and immune regulation of the product.

The revenue for Immune globulin (human) is expected to reach a total of $2.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Immune globulin (human) NPV Report.

Immune globulin (human) is currently owned by Hualan Biological Engineering.

Immune globulin (human) Overview

Human immunoglobulin (Human Immunoglobulin (PH4)) contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. It is formulated as solution for intravenous, and intramuscular route of administration. It is indicated for the treatment of primary immunodeficiency syndromes such as primary immunoglobulin deficiency diseases, such as X-linked hypoimmunoglobinemia, common variable immunodeficiency disease (CVID), IgG subclass deficiency, secondary immunoglobulin deficiency diseases, such as severe infections, neonatal sepsis, autoimmune diseases (AID), such as primary thrombocytopenic purpura, Kawasaki disease (KD), to prevent measles and infectious hepatitis.

Hualan Biological Engineering Overview

Hualan Biological Engineering (Hualan Biological) is a biopharmaceutical company that carries out research, development and commercialization of blood products, vaccines, recombinant proteins and other biological products. The company’s product portfolio includes hepatitis b human immunoglobulin, human albumin, intravenous human immunoglobulin (pH4), human immunoglobulin, tetanus human immunoglobulin, and freeze-dried human fibrin glue. It also provides products such as zymogen complex, human coagulation factor VIII, human fibrinogen, and rabies immune globulin. Hualan Biological offers blood products under the brand Hualan. The company’s products are used in the treatment of hypoalbuminemia, distress syndrome, immunodeficiency disease, bacterial and viral infections, hepatitis B, and hemophilia A. It operates manufacturing facilities in China. Hualan Biological is headquartered in Xinxiang, Henan, China.

The company reported revenues of (Renminbi) CNY4,436.2 million for the fiscal year ended December 2021 (FY2021), a decrease of 11.7% over FY2020. In FY2021, the company’s operating margin was 37.8%, compared to an operating margin of 42.8% in FY2020. In FY2021, the company recorded a net margin of 29.3%, compared to a net margin of 32.1% in FY2020. The company reported revenues of CNY1,252.9 million for the third quarter ended September 2022, a decrease of 26.7% over the previous quarter.

Quick View – Immune globulin (human)

Report Segments
  • Innovator (NME)
Drug Name
  • Immune globulin (human)
Administration Pathway
  • Intramuscular
  • Intravenous
Therapeutic Areas
  • Gastrointestinal
  • Hematological Disorders
  • Immunology
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.